The effects of dual-task training with different task priorities on physical performance and cognitive status in patients with Parkinson's disease: a single-blind, randomized controlled trial.

Neurol SciSep 29, 2026 (epub)
Clinical ResearchNeurologyPhysical Medicine & Rehabilitation

Elvan Özcan Gülşen, Fatih Söke, Çağrı Gülşen et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the effects of variable-priority dual-task training (V-DTT) and fixed-priority dual-task training (F-DTT) on physical performance and cognitive status in 30 patients with Parkinson's disease. Both DTT methods improved various motor and cognitive functions, but V-DTT showed superior benefits in executive functions and processing speed compared to single-task training (STT).

Key findings

  • Both DTT groups improved motor symptoms and activities of daily living significantly.
  • Only DTT groups showed enhancements in executive functions, attention, and verbal fluency.
  • V-DTT outperformed F-DTT in improving processing speed and dual-tasking ability.

Why it matters

Understanding the differential effects of dual-task training strategies can help clinicians optimize rehabilitation programs for patients with Parkinson's disease, potentially enhancing both physical and cognitive outcomes.

Source

PubMed · PMID 42809128

Published in Neurol Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.